<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02863536</url>
  </required_header>
  <id_info>
    <org_study_id>OPEFF/0116/MD</org_study_id>
    <nct_id>NCT02863536</nct_id>
  </id_info>
  <brief_title>A Study of the New Medical Device Polybactum®</brief_title>
  <acronym>POLARIS</acronym>
  <official_title>A Multicenter, Open Label, Non-comparative, 3 Months Study to Assess the Performance and Safety of the New Medical Device Polybactum® in Reducing the Frequency of Recurrent Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Effik Italia S.p.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Opera Contract Research Organization SRL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Effik Italia S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The POLARIS trial is designed as a multicenter, open label, non-comparative, 3 months,
      clinical study.

      Interventional, non-controlled, multicenter trial with a prospective design on one cohort of
      patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy of Polybactum® administered for 3 cycles (one cycle/month) in
      reducing the rate of recurrence of BV in women cured with vaginal metronidazole and to
      compare the results of the treatment with the rate of recurrence reported in appropriate
      selected international literature. Therefore, the Polybactum® early administration should be
      able to modify the basal individual risk of BV recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amsel criteria laboratory diagnostic</measure>
    <time_frame>3 months</time_frame>
    <description>Signs and symptoms of Bacterial Vaginosis assesed also by patients diary (vaginal discharge, burning, erythema, dyspareunia)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lactobacilli counting</measure>
    <time_frame>3 months</time_frame>
    <description>The rate of return to normality of vaginal microflora through Lactobacilli counting</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient's diary</measure>
    <time_frame>3 months</time_frame>
    <description>Global Assessment of Efficacy by Patient's diary</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Polybactum®</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Polybactum® ovules are administered intravaginally on 3 cycles, 1 cycle per month.
Polybactum is a medical device Class IIa used and marketed for the recurrence of Bacterial Vaginosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polybactum®</intervention_name>
    <description>3 cycles treatment one per month.. Duration of one cycle: 1 week; administration for each cycle: 1 ovule at Day 1, 1 ovule at Day 4; 1 ovule at Day 7.In the two following cycles, the same treatment will be repeated immediately after the end of the first and second menstrual bleeding.</description>
    <arm_group_label>Polybactum®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women above 18 years.

          -  BV diagnosed by Amsel criteria (see Annex 3) in the 6-9 days before study, and cured
             with metronidazole vaginal formulation (gel for 5 days or ovules for 7 days).

          -  Diagnosis of RBV (at least 2 episodes of BV in the last 12 months including the BV
             cured before baseline).

          -  Non lactating women or lactating non amenorrheic women.

          -  Read and signed informed consent.

        Exclusion Criteria:

          -  Pregnancy.

          -  Candidiasis or mixed vaginitis.

          -  HIV or other immunodeficiency.

          -  Known allergy to metronidazole or to Polybactum® ingredients.

          -  Sex workers.

          -  Menstruation or pre-menopause/menopause.

          -  Patients concomitantly included in different interventional clinical trials.

          -  Unwillingness to provide the informed consent to the trial.

          -  Time between the last day of last menses and baseline visit &gt; 16 days or ≤5 days.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Murina, Prof.dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servizio di Patologia del Tratto Genitale Inferiore U.O. Ostetricia e Ginecologia Ospedale Vittore Buzzi - Universita' degli Studi di Milano Milano (Italy)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barattini Dionisio, MD</last_name>
    <phone>+40 774 012684</phone>
    <email>barattini@operacro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Serban Rosu, MD</last_name>
    <phone>040722313224</phone>
    <email>rosu@operacro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Opera Contract Research Organization Srl</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300209</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramona Petrita</last_name>
      <phone>040721893630</phone>
      <email>ramona.petrita@operacro.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <reference>
    <citation>Schwebke JR. Bacterial vaginosis--more questions than answers. Genitourin Med. 1997 Oct;73(5):333-4.</citation>
    <PMID>9534738</PMID>
  </reference>
  <reference>
    <citation>Sobel JD. Antibiotic consideration in bacterial vaginosis. Curr Infect Dis Rep. 2009 Nov;11(6):471-5.</citation>
    <PMID>19857387</PMID>
  </reference>
  <reference>
    <citation>Marrazzo JM. Interpreting the epidemiology and natural history of bacterial vaginosis: are we still confused? Anaerobe. 2011 Aug;17(4):186-90. doi: 10.1016/j.anaerobe.2011.03.016. Epub 2011 Apr 16. Review.</citation>
    <PMID>21524714</PMID>
  </reference>
  <reference>
    <citation>Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, Kuzevska I, Fairley CK. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006 Jun 1;193(11):1478-86. Epub 2006 Apr 26.</citation>
    <PMID>16652274</PMID>
  </reference>
  <reference>
    <citation>Donders GG. Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol. 2007 Jun;21(3):355-73. Epub 2007 Apr 16. Review.</citation>
    <PMID>17434799</PMID>
  </reference>
  <reference>
    <citation>Kovachev S, Dobrevski-Vacheva R. [Probiotic monotherapy of bacterial vaginosis: a open, randomized trial]. Akush Ginekol (Sofiia). 2013;52 Suppl 1:36-42. Bulgarian.</citation>
    <PMID>24294744</PMID>
  </reference>
  <reference>
    <citation>Falagas M, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect. 2007 Jul;13(7):657-64. Review.</citation>
    <PMID>17633390</PMID>
  </reference>
  <reference>
    <citation>Vujic G, Jajac Knez A, Despot Stefanovic V, Kuzmic Vrbanovic V. Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2013 May;168(1):75-9. doi: 10.1016/j.ejogrb.2012.12.031. Epub 2013 Feb 7.</citation>
    <PMID>23395559</PMID>
  </reference>
  <reference>
    <citation>Swidsinski A, Mendling W, Loening-Baucke V, Ladhoff A, Swidsinski S, Hale LP, Lochs H. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005 Nov;106(5 Pt 1):1013-23.</citation>
    <PMID>16260520</PMID>
  </reference>
  <reference>
    <citation>Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006289. doi: 10.1002/14651858.CD006289.pub2. Review.</citation>
    <PMID>19821358</PMID>
  </reference>
  <reference>
    <citation>Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, Forbes C, Glanville J, Hicks NJ, Moody J, Twaddle S, Timimi H, Young P. How to formulate research recommendations. BMJ. 2006 Oct 14;333(7572):804-6. Review.</citation>
    <PMID>17038740</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrence of Bacterial Vaginosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

